Clinical Trial Update: Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated early administration of Romidepsin and the HIV broadly neutralizing antibody 3BNC117 in treatment-naïve patients starting ART; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 3BNC117
• Romidepsin (romidepsin)

Snippet

Sponsor: Aarhus University Hospital | Conditions: Hiv | Phase 2 | Status: COMPLETED